What is recombinant monoclonal antibody production?

Recombinant monoclonal antibody production is the manufacturing of antibodies using recombinant DNA technology — expressing defined antibody sequences in mammalian cell systems (typically CHO) rather than relying on hybridoma cells or biological sources. Recombinant production offers complete sequence definition, lot-to-lot consistency, scalability, and the ability to incorporate Fc or CDR engineering modifications.

What scale of antibody production does AntibodyLLM offer?

AntibodyLLM supports antibody production from milligram research scale (1–10 mg from transient expression) to gram scale (1–100 g from stable CHO cell bioreactor production). Specific scales include: transient expression (1–100 mg), small-scale stable production (100 mg–5 g), and scale-up bioreactor production (5 g–1 kg+). Contact us for requirements outside these ranges.

What purity levels can AntibodyLLM achieve for monoclonal antibody production?

AntibodyLLM routinely achieves >95% purity (by SEC-HPLC) for monoclonal antibody products using a standard protein A capture and polishing purification workflow. For therapeutic-grade material, purity >99% is achievable with additional ion exchange and hydrophobic interaction chromatography steps. HCP, DNA, and endotoxin levels are controlled to meet research or clinical specifications.

What antibody formats can AntibodyLLM produce?

AntibodyLLM produces: full-length IgG antibodies (IgG1, IgG2, IgG4 subclasses), bispecific antibodies (multiple formats), Fab and F(ab')2 fragments, scFv and VHH (nanobody) formats, Fc-fusion proteins, and antibody-drug conjugate (ADC) precursors with engineered cysteines or non-natural amino acids for site-specific conjugation.

How long does monoclonal antibody production take?

Timelines depend on scale and starting material. Transient expression production (1–100 mg): 2–4 weeks from gene synthesis to purified protein. Stable cell line production (gram scale): 10–16 weeks for cell line development plus 4–8 weeks for production runs. Rush transient expression (research-grade) can be completed in 10–14 days.

Is GMP-compatible antibody production available at AntibodyLLM?

Yes. AntibodyLLM's production workflow is designed to be GMP-compatible, with full batch records, in-process controls, and QC release testing. We provide material suitable for preclinical safety studies (GLP-compliant) and clinical trial supply (IND-enabling). Full GMP production for commercial supply can be arranged through our network of certified CMO partners.

Monoclonal Antibody Production — AntibodyLLM | mg to Gram Scale CHO Manufacturing

Recombinant Antibody Production Overview

Recombinant monoclonal antibody production is the cornerstone of modern biopharmaceutical manufacturing and research reagent supply. Unlike hybridoma-derived antibodies, recombinant production uses a defined antibody sequence expressed in a controlled mammalian cell system — providing complete sequence transparency, superior lot-to-lot consistency, and unlimited scalability.

AntibodyLLM's CHO bioreactor platform supports the full production journey: from rapid milligram-scale material for early research and assay development, through gram-scale production for in vivo studies and IND-enabling work, to kilogram-scale commercial manufacturing. Each production run is accompanied by comprehensive analytical QC and batch documentation.

Our integrated platform combines AI antibody design with stable cell line development and bioreactor production, enabling seamless handoffs from sequence to purified protein without the coordination overhead of multiple CRO vendors.

Production Scale Options

Scale	Expression System	Yield	Timeline	Application
Micro-scale	Transient CHO, 96-well/shake flask	0.1–5 mg	1–2 weeks	Binding screening, SPR/BLI
Research-scale	Transient CHO, 1–2 L bioreactor	5–100 mg	2–4 weeks	Assay development, in vitro studies
Pilot-scale	Stable CHO, 10–50 L bioreactor	1–50 g	12–20 weeks	In vivo studies, IND-enabling
Manufacturing-scale	Stable CHO, 200–2000 L bioreactor	50 g–1 kg+	Custom	Clinical supply, commercial

Production Workflow

Gene Synthesis & Vector Construction

Codon-optimized VH/VL sequences cloned into proprietary expression vector with selected IgG subclass backbone. Signal peptide and Fc optimization for maximum secretion efficiency.

Transfection & Expression

Transient transfection (PEI or electroporation) of CHO-S suspension cultures for rapid production. Stable cell line platform used for repeat or scale-up orders for superior consistency.

Clarification & Capture Purification

Conditioned medium clarification by depth and sterile filtration. Protein A affinity chromatography for IgG capture (>95% capture purity). Alternative capture resins for non-Fc formats.

Polishing & Formulation

Ion exchange and SEC polishing steps for high-purity therapeutic-grade material. Buffer exchange to client-specified formulation. Sterile filtration (0.22 μm) and aliquoting.

QC Release Testing & Delivery

Full QC panel: SDS-PAGE, SEC-HPLC, protein concentration (A280), endotoxin (LAL), sterility, binding activity (ELISA). CoA and full batch record provided. Shipped on dry ice with temperature monitoring.

Quality Specifications

Standard Research Grade

Purity >95% by SEC-HPLC
Endotoxin <5 EU/mg
Binding confirmed by ELISA
CoA and SDS-PAGE image

GMP-Compatible Clinical Grade

Purity >99% by SEC-HPLC
Endotoxin <1 EU/mg
Sterility tested
Full batch record, HCP/DNA testing

Supported Antibody Formats

IgG1 / IgG4

Full-length therapeutic mAbs with native Fc function

Bispecific IgG

Knob-into-hole, CrossMab dual-targeting formats

Fab / F(ab')2

Fragment formats for imaging, rapid clearance

scFv / VHH

Single-chain and nanobody formats for intrabodies and CAR-T

Fc-Fusion Proteins

Cytokine-Fc, receptor-Fc, enzyme-Fc fusions

ADC Precursors

Engineered for site-specific payload conjugation

Frequently Asked Questions

What is the difference between transient and stable antibody production?

Transient production introduces the gene transiently without genomic integration, producing protein for 7–14 days. It is fast (2–4 weeks) and ideal for early research quantities. Stable production uses a permanent genomic integration for continuous, reproducible manufacturing. Stable production is required for clinical-grade material and repeat large-scale orders.

Can AntibodyLLM produce antibodies from my hybridoma cell line?

Yes. We can sequence antibodies from your hybridoma by RNA extraction and 5' RACE or NGS antibody sequencing, then express the recombinant sequence in CHO for superior consistency, scalability, and quality compared to hybridoma production. This also provides IP-protected sequence ownership.

What QC tests are performed on each antibody production batch?

Standard QC includes: SDS-PAGE (reducing and non-reducing), SEC-HPLC purity, protein concentration (A280 and BCA), endotoxin (LAL), binding activity (ELISA), and glycan analysis (for glycoengineered antibodies). Clinical-grade batches additionally include sterility testing, HCP ELISA, residual DNA, protein A leachable, and charge variant analysis (IEF/CEX).

How do I get a production quote?

Contact us with: antibody format (IgG subtype, bispecific, etc.), required quantity and purity grade, delivery timeline, and whether you have a validated cell line or need us to develop one. We typically provide a quote and timeline estimate within 24–48 business hours.

Does AntibodyLLM offer bispecific antibody production?

Yes. AntibodyLLM specializes in bispecific antibody production including knob-into-hole IgG, CrossMab, DART, and tandem scFv formats. Our AI platform designs chain pairing strategies to minimize mispairing, and our purification workflow consistently achieves >90% bispecific purity before final polishing.

What is the minimum order quantity?

There is no minimum order quantity for research-grade production. We produce from as little as 0.1 mg (for screening purposes) upwards. For GMP-compatible clinical production, minimum batch sizes typically start at 1 g due to the QC and documentation requirements involved.

Monoclonal Antibody Production